Consensus statement on essential patient characteristics in systemic treatment trials for metastatic colorectal cancer: Supported by the ARCAD Group

Goey, K.K.H.Sørbye, H.Glimelius, B.Adams, R.A.André, T.Arnold, D.Berlin, J.D.Bodoky, G.de Gramont, A.Díaz-Rubio, E.Eng, C.Falcone, A.Grothey, A.Heinemann, V.Hochster, H.S.Kaplan, R.S.Kopetz, S.Labianca, R.Lieu, C.H.Meropol, N.J.et al.2018-10-112018-10-112018European Journal of Cancer, 2018; 100:35-450959-80491879-0852http://hdl.handle.net/2440/115003Available online 22 June 2018Abstract not availableen© 2018 Elsevier Ltd. All rights reserved.Colorectal cancerMetastatic diseasePatient characteristicsPrognosisStratificationClinical trialsDelphi surveyConsensus statement on essential patient characteristics in systemic treatment trials for metastatic colorectal cancer: Supported by the ARCAD GroupJournal article003009158210.1016/j.ejca.2018.05.0102-s2.0-85048766700427502Price, T.J. [0000-0002-3922-2693]